Ceralasertib + carboplatin

Ceralasertib (AZD6738) is a potent and selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase, developed as an anticancer agent by AstraZeneca. By inhibiting ATR-mediated signaling, it disrupts DNA damage checkpoint activation and repair, leading to tumor cell apoptosis. Carboplatin is a cytotoxic platinum-based chemotherapy that acts primarily by alkylating DNA, causing cross-linking and preventing replication or transcription. The combination of ceralasertib with carboplatin aims to enhance antitumor activity by exploiting synthetic lethality in tumors with defective DNA repair mechanisms or high replication stress. This combination has been studied in phase I/II trials for advanced solid tumors including ovarian, lung, gastric, breast cancers, and others[1][2][5][7].

Other names

ceralasertib + carboplatin